Literature DB >> 20923685

Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia.

Antonella Zucchetto1, Ilaria Cattarossi, Paola Nanni, Eva Zaina, Giuseppina Prato, Milena Gilestro, Daniela Marconi, Pietro Bulian, Francesca M Rossi, Luigi Del Vecchio, Paola Omedè, Massimo Geuna, Giovanni Del Poeta, Valter Gattei.   

Abstract

Studies of gene expression profiling have been successfully used for the identification of molecules to be employed as potential prognosticators. In analogy with gene expression profiling, we have previously proposed an original method to identify the immunophenotypic signature of chronic lymphocytic leukemia (CLL) subsets with different prognosis, named surface-antigen expression profiling. According to this method, expression data for surface markers can be successfully analyzed by data mining tools identical to those employed in gene expression profiling studies, including unsupervised and supervised algorithms, with the aim to identify the immunophenotypic signature of CLL subsets with different prognosis. By employing an identical approach for investigating the reactivity of a wide panel of monoclonal antibodies provided by the "Ninth International Workshop on Leukocyte Differentiation Antigens", we were able to identify some of them (i.e. TCL1, CCR7, FCRL2, FCRL3, and CD150) as additional potential markers with prognostic relevance in CLL. These suggestions need to be confirmed: (i) in a new set of clinically characterized CLL cases; (ii) in combination with other prognostic markers in the context of comprehensive scoring systems for clinical outcome prediction.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923685     DOI: 10.1016/j.imlet.2010.09.017

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

1.  Integrated machine learning pipeline for aberrant biomarker enrichment (i-mAB): characterizing clusters of differentiation within a compendium of systemic lupus erythematosus patients.

Authors:  Trang T Le; Nigel O Blackwood; Jaclyn N Taroni; Weixuan Fu; Matthew K Breitenstein
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

2.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

3.  Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses.

Authors:  Marta Cuenca; Xavier Romero; Jordi Sintes; Cox Terhorst; Pablo Engel
Journal:  J Immunol       Date:  2015-12-14       Impact factor: 5.422

Review 4.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

5.  The observation report of red blood cell morphology in Thailand teenager by using data mining technique.

Authors:  Sarawut Saichanma; Sucha Chulsomlee; Nonthaya Thangrua; Pornsuri Pongsuchart; Duangmanee Sanmun
Journal:  Adv Hematol       Date:  2014-02-13

6.  Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy.

Authors:  Pauline Gonnord; Manon Costa; Arnaud Abreu; Michael Peres; Loïc Ysebaert; Sébastien Gadat; Salvatore Valitutti
Journal:  Oncoimmunology       Date:  2019-02-07       Impact factor: 8.110

7.  Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential.

Authors:  Joanne H Lee; Shuai Shao; Michelle Kim; Stacey M Fernandes; Jennifer R Brown; Lance C Kam
Journal:  Front Cell Dev Biol       Date:  2021-04-09

Review 8.  Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Authors:  Carlos Cuesta-Mateos; Jennifer R Brown; Fernando Terrón; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

9.  A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.

Authors:  Burcu Yigit; Peter J Halibozek; Shih-Shih Chen; Michael S O'Keeffe; Jon Arnason; David Avigan; Valter Gattei; Atul Bhan; Osman Cen; Richard Longnecker; Nicholas Chiorazzi; Ninghai Wang; Pablo Engel; Cox Terhorst
Journal:  Oncotarget       Date:  2016-05-03

10.  The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.

Authors:  Inna Gordiienko; Larysa Shlapatska; Valeriia Kholodniuk; Lilia Sklyarenko; Daniel F Gluzman; Edward A Clark; Svetlana P Sidorenko
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.